Skip to main content

Advertisement

Depression and MDD Learning Library

Featured

Andrew Penn
Clinical Pearls
08/08/2024
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS,...
08/08/2024
Psych Congress NP Institute
amber and brooke
Rapid Refresh
04/10/2024
Amber Hoberg, NP, and Brooke Kemf answer the audience-posed question, "What are the differences between major depressive disorder (MDD) with mixed features and bipolar I disorder?"
Amber Hoberg, NP, and Brooke Kemf answer the audience-posed question, "What are the differences between major depressive disorder (MDD) with mixed features and bipolar I disorder?"
Amber Hoberg, NP, and Brooke...
04/10/2024
Psych Congress NP Institute
Brooke Kempf
Clinical Pearls
04/03/2024
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC,...
04/03/2024
Psych Congress NP Institute

Rapid Refreshers

amber and brooke
Rapid Refresh
04/10/2024
Amber Hoberg, NP, and Brooke Kemf answer the audience-posed question, "What are the differences between major depressive disorder (MDD) with mixed features and bipolar I disorder?"
Amber Hoberg, NP, and Brooke Kemf answer the audience-posed question, "What are the differences between major depressive disorder (MDD) with mixed features and bipolar I disorder?"
Amber Hoberg, NP, and Brooke...
04/10/2024
Psych Congress NP Institute
Julie Carbray
Rapid Refresh
07/26/2024
Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, provides a quick overview of some of the most widely accessible screening tools for pediatric and adult attention-deficit/hyperactivity disorder.  
Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, provides a quick overview of some of the most widely accessible screening tools for pediatric and adult attention-deficit/hyperactivity disorder.  
Julie Carbray, PhD, FPMHNP-BC,...
07/26/2024
Psych Congress NP Institute
andrew and julie
Rapid Refresh
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
amber and brooke
Rapid Refresh
04/10/2024
Amber Hoberg, NP, and Brooke Kemf answer the audience-posed question, "What are the differences between major depressive disorder (MDD) with mixed features and bipolar I disorder?"
Amber Hoberg, NP, and Brooke Kemf answer the audience-posed question, "What are the differences between major depressive disorder (MDD) with mixed features and bipolar I disorder?"
Amber Hoberg, NP, and Brooke...
04/10/2024
Psych Congress NP Institute

Clinical Pearls

Andrew Penn
Clinical Pearls
08/08/2024
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS,...
08/08/2024
Psych Congress NP Institute
Brooke Kempf
Clinical Pearls
04/03/2024
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC,...
04/03/2024
Psych Congress NP Institute
Andrew Penn
Clinical Pearls
08/08/2024
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS,...
08/08/2024
Psych Congress NP Institute
Desiree Matthews
Clinical Pearls
07/19/2024
Gain insights into the considerations for initiating LAI antipsychotics and optimizing therapeutic plasma concentrations with Psych Congress NP Institute Steering Committee Member Desiree Matthews, PMHNP-BC.
Gain insights into the considerations for initiating LAI antipsychotics and optimizing therapeutic plasma concentrations with Psych Congress NP Institute Steering Committee Member Desiree Matthews, PMHNP-BC.
Gain insights into the...
07/19/2024
Psych Congress NP Institute
Brooke Kempf
Clinical Pearls
04/03/2024
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC,...
04/03/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute